Reassessment of inclusion on the list of drugs reimbursed by National Health Insurance and of the improvement in actual benefit of beta interferons and glatiramer acetate indicated in multiple sclerosis.
-
Clinical Benefit
Substantial
The actual benefit of this medicinal product remains substantial.
Clinical Added Value
moderate
In view of the absence of demonstrated long-term efficacy against disability provided by the medicinal product BETAFERON, the improvement in actual benefit is level III in the treatment of patients with multiple sclerosis.
Listen
